It will be a base for medical and scientific communications staff ahead of three phase IIb trials in the US of its CTX and hRPC cell therapy candidates in people recovering from strokes and patients with retinal diseases.
Having a presence Stateside will allow ReNeuron to more closely manage its relationship with the clinical research organisations carrying out the studies, the company said.
It will also allow the UK research group to establish stronger ties with key opinion leaders in America, it added.
"We are delighted to have established operations in Boston, one of the US's most vibrant academic and commercial biotechnology hubs,” said Olav Hellebø, chief executive.
“The US is a major future market for our cell-based therapies and a presence on the ground represents a key element of ReNeuron's clinical and commercial development strategy as our therapeutic candidates move closer to market."